Innospec Inc (IOSP) - Net Assets
Based on the latest financial reports, Innospec Inc (IOSP) has net assets worth $1.30 Billion USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.80 Billion) and total liabilities ($496.50 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check IOSP cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.30 Billion |
| % of Total Assets | 72.41% |
| Annual Growth Rate | 5.52% |
| 5-Year Change | 28.7% |
| 10-Year Change | 100.91% |
| Growth Volatility | 23.17 |
Innospec Inc - Net Assets Trend (1998–2024)
This chart illustrates how Innospec Inc's net assets have evolved over time, based on quarterly financial data. Also explore how large is Innospec Inc's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Innospec Inc (1998–2024)
The table below shows the annual net assets of Innospec Inc from 1998 to 2024. For live valuation and market cap data, see Innospec Inc (IOSP) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $1.22 Billion | +5.78% |
| 2023-12-31 | $1.15 Billion | +10.50% |
| 2022-12-31 | $1.04 Billion | +0.72% |
| 2021-12-31 | $1.03 Billion | +9.32% |
| 2020-12-31 | $944.90 Million | +2.83% |
| 2019-12-31 | $918.90 Million | +11.31% |
| 2018-12-31 | $825.50 Million | +3.93% |
| 2017-12-31 | $794.30 Million | +21.49% |
| 2016-12-31 | $653.80 Million | +8.01% |
| 2015-12-31 | $605.30 Million | +17.33% |
| 2014-12-31 | $515.90 Million | +26.01% |
| 2013-12-31 | $409.40 Million | +29.15% |
| 2012-12-31 | $317.00 Million | -7.61% |
| 2011-12-31 | $343.10 Million | +14.10% |
| 2010-12-31 | $300.70 Million | +90.80% |
| 2009-12-31 | $157.60 Million | -31.27% |
| 2008-12-31 | $229.30 Million | -15.54% |
| 2007-12-31 | $271.50 Million | +20.61% |
| 2006-12-31 | $225.10 Million | -28.47% |
| 2005-12-31 | $314.70 Million | -29.44% |
| 2004-12-31 | $446.00 Million | +2.11% |
| 2003-12-31 | $436.80 Million | +18.99% |
| 2002-12-31 | $367.10 Million | +23.89% |
| 2001-12-31 | $296.30 Million | -1.27% |
| 2000-12-31 | $300.10 Million | -5.12% |
| 1999-12-31 | $316.30 Million | +5.05% |
| 1998-12-31 | $301.10 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Innospec Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2468.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $1.02 Billion | 84.63% |
| Common Stock | $300.00K | 0.02% |
| Other Comprehensive Income | $-91.00 Million | -7.51% |
| Other Components | $276.90 Million | 22.86% |
| Total Equity | $1.21 Billion | 100.00% |
Innospec Inc Competitors by Market Cap
The table below lists competitors of Innospec Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
$1.90 Billion |
|
Shaanxi Yanchang Petroleum Chemical Engineering Co Ltd
SHG:600248
|
$1.90 Billion |
|
Tecnoglass Inc
NYSE:TGLS
|
$1.90 Billion |
|
Grand City Properties SA
F:GYC
|
$1.91 Billion |
|
Newell Rubbermaid Inc.
NASDAQ:NWL
|
$1.90 Billion |
|
Babcock & Wilcox Enterprises Inc
NYSE:BW
|
$1.90 Billion |
|
Grupo Lamosa S.A.B. de C.V
MX:LAMOSA
|
$1.90 Billion |
|
Compañía Cervecerías Unidas S.A
F:CVU
|
$1.90 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Innospec Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,147,100,000 to 1,211,200,000, a change of 64,100,000 (5.6%).
- Net income of 35,600,000 contributed positively to equity growth.
- Dividend payments of 38,800,000 reduced retained earnings.
- Share repurchases of 700,000 reduced equity.
- New share issuances of 2,100,000 increased equity.
- Other comprehensive income increased equity by 57,100,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $35.60 Million | +2.94% |
| Dividends Paid | $38.80 Million | -3.2% |
| Share Repurchases | $700.00K | -0.06% |
| Share Issuances | $2.10 Million | +0.17% |
| Other Comprehensive Income | $57.10 Million | +4.71% |
| Other Changes | $8.80 Million | +0.73% |
| Total Change | $- | 5.59% |
Book Value vs Market Value Analysis
This analysis compares Innospec Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.59x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 7.41x to 1.59x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1998-12-31 | $10.37 | $76.83 | x |
| 1999-12-31 | $11.23 | $76.83 | x |
| 2000-12-31 | $11.37 | $76.83 | x |
| 2001-12-31 | $11.67 | $76.83 | x |
| 2002-12-31 | $14.44 | $76.83 | x |
| 2003-12-31 | $17.11 | $76.83 | x |
| 2004-12-31 | $17.16 | $76.83 | x |
| 2005-12-31 | $12.71 | $76.83 | x |
| 2006-12-31 | $8.88 | $76.83 | x |
| 2007-12-31 | $10.93 | $76.83 | x |
| 2008-12-31 | $9.40 | $76.83 | x |
| 2009-12-31 | $6.38 | $76.83 | x |
| 2010-12-31 | $12.12 | $76.83 | x |
| 2011-12-31 | $13.96 | $76.83 | x |
| 2012-12-31 | $13.29 | $76.83 | x |
| 2013-12-31 | $16.95 | $76.83 | x |
| 2014-12-31 | $20.74 | $76.83 | x |
| 2015-12-31 | $24.59 | $76.83 | x |
| 2016-12-31 | $26.75 | $76.83 | x |
| 2017-12-31 | $32.44 | $76.83 | x |
| 2018-12-31 | $33.55 | $76.83 | x |
| 2019-12-31 | $37.14 | $76.83 | x |
| 2020-12-31 | $38.11 | $76.83 | x |
| 2021-12-31 | $41.54 | $76.83 | x |
| 2022-12-31 | $41.55 | $76.83 | x |
| 2023-12-31 | $45.84 | $76.83 | x |
| 2024-12-31 | $48.22 | $76.83 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Innospec Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.94%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.93%
- • Asset Turnover: 1.06x
- • Equity Multiplier: 1.43x
- Recent ROE (2.94%) is below the historical average (9.52%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1998 | 23.38% | 15.14% | 0.58x | 2.68x | $40.29 Million |
| 1999 | 13.57% | 8.24% | 0.61x | 2.71x | $11.21 Million |
| 2000 | 6.19% | 4.33% | 0.60x | 2.37x | $-11.26 Million |
| 2001 | 1.93% | 1.33% | 0.53x | 2.72x | $-23.44 Million |
| 2002 | 14.37% | 11.54% | 0.60x | 2.06x | $15.85 Million |
| 2003 | 12.04% | 11.21% | 0.62x | 1.72x | $8.78 Million |
| 2004 | 1.39% | 1.29% | 0.61x | 1.77x | $-38.38 Million |
| 2005 | -39.34% | -23.44% | 0.78x | 2.15x | $-155.14 Million |
| 2006 | 5.07% | 2.14% | 0.94x | 2.53x | $-11.10 Million |
| 2007 | 10.87% | 4.90% | 1.09x | 2.03x | $2.35 Million |
| 2008 | 5.45% | 1.95% | 1.30x | 2.16x | $-10.43 Million |
| 2009 | 4.06% | 1.07% | 1.10x | 3.45x | $-9.36 Million |
| 2010 | 24.51% | 10.79% | 1.25x | 1.82x | $43.63 Million |
| 2011 | 14.25% | 6.31% | 1.36x | 1.66x | $14.59 Million |
| 2012 | 21.55% | 8.80% | 1.34x | 1.83x | $36.60 Million |
| 2013 | 19.00% | 9.50% | 1.03x | 1.94x | $36.86 Million |
| 2014 | 16.30% | 8.75% | 0.96x | 1.94x | $32.51 Million |
| 2015 | 19.74% | 11.80% | 0.98x | 1.70x | $58.97 Million |
| 2016 | 12.43% | 9.20% | 0.75x | 1.81x | $15.92 Million |
| 2017 | 7.78% | 4.73% | 0.93x | 1.78x | $-17.63 Million |
| 2018 | 10.30% | 5.76% | 1.00x | 1.78x | $2.45 Million |
| 2019 | 12.22% | 7.41% | 1.03x | 1.60x | $20.35 Million |
| 2020 | 3.04% | 2.41% | 0.85x | 1.48x | $-65.74 Million |
| 2021 | 9.02% | 6.28% | 0.94x | 1.52x | $-10.14 Million |
| 2022 | 12.81% | 6.77% | 1.22x | 1.54x | $29.20 Million |
| 2023 | 12.13% | 7.14% | 1.14x | 1.49x | $24.39 Million |
| 2024 | 2.94% | 1.93% | 1.06x | 1.43x | $-85.52 Million |
Industry Comparison
This section compares Innospec Inc's net assets metrics with peer companies in the Specialty Chemicals industry.
Industry Context
- Industry: Specialty Chemicals
- Average net assets among peers: $2,020,671,219
- Average return on equity (ROE) among peers: 8.06%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Innospec Inc (IOSP) | $1.30 Billion | 23.38% | 0.38x | $1.90 Billion |
| Albemarle Corp (ALB) | $4.09 Billion | 13.03% | 1.41x | $19.80 Billion |
| Alto Ingredients Inc (ALTO) | $225.06 Million | -26.21% | 0.78x | $212.84 Million |
| Aemetis Inc (AMTX) | $-22.20 Million | 0.00% | 0.00x | $154.69 Million |
| Air Products and Chemicals Inc (APD) | $11.18 Billion | 13.40% | 0.72x | $62.29 Billion |
| Ashland Global Holdings Inc (ASH) | $1.44 Billion | 10.05% | 2.77x | $2.37 Billion |
| Avient Corp (AVNT) | $1.71 Billion | 7.69% | 1.85x | $3.16 Billion |
| Axalta Coating Systems Ltd (AXTA) | $1.54 Billion | 17.15% | 3.69x | $5.92 Billion |
| Balchem Corporation (BCPC) | $2.80 Million | 14.29% | 1.07x | $5.17 Billion |
| BioNexus Gene Lab Corp Common stock (BGLC) | $7.18 Million | 10.47% | 0.33x | $4.91 Million |
| Bon Natural Life Ltd (BON) | $30.09 Million | 20.73% | 0.24x | $7.91 Million |
About Innospec Inc
Innospec Inc. develops, manufactures, blends, markets, and supplies specialty chemicals in the Americas, Europe, the Middle East, Africa, and Asia-Pacific. It operates through three segments: Performance Chemicals, Fuel Specialties, and Oilfield Services. The company offers specialty chemical products used as additives in diesel, jet, marine, fuel oil and other fuels used in the operation of comm… Read more